Jubilant Life Sciences’ material wholly owned subsidiary- Jubilant Pharma (JPL) through one of its wholly owned subsidiaries, has signed an Asset Purchase Agreement with Triad Isotopes Inc. (Triad) and its parent, Isotope Holdings, Inc. to acquire substantially all of the assets which comprise the radiopharmacy business of Triad. The closing of the transaction is subject to customary closing conditions, including contract, regulatory and other approvals. The acquisition will be funded through JPL’s internal accruals and is likely to be earnings accretive in the first full year of operations.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
